(function(){
			var content_array=["<p><strong>About Caprion Proteomics<\/strong><\/p>\r\n<p>Caprion is the leading provider of proteomics biomarker and immune monitoring services to the pharmaceutical and biotechnology industry. Its proprietary proteomics technology, CellCarta&reg;, is a gel-free, label-free mass spectrometry (MS) platform that enables a comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Its proprietary immune monitoring platform, ImmuneCarta&reg;, offers multiparametric flow cytometry analysis for functional analyses of innate and adaptive immune responses. Caprion also leverages CellCarta&reg; to develop its own&nbsp;<a rel=\"nofollow\" href=\"http:\/\/www.caprion.com\/en\/in-vitro-diagnostics\/pipeline.php\" target=\"_blank\">in-vitro diagnostic products<\/a>&nbsp;targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion also serves as a biomarker center of excellence for the U.S. Government\/NIH-NIAID for Biodefense research. Caprion acquired PPD Biomarker Discovery Sciences, LLC from PPD Inc. in 2010, and the assets of the National Immune Monitoring Laboratory in 2011. Caprion Proteomics, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit&nbsp;<a rel=\"nofollow\" href=\"http:\/\/www.caprion.com\/\" target=\"_blank\">www.caprion.com<\/a>.<\/p>\r\n<p><strong>About Indi<\/strong><\/p>\r\n<p>Indi (Integrated Diagnostics) is creating powerful new tools to help physicians manage complex diseases with a non-invasive blood test. The company's first test measures multiple blood proteins linked to pulmonary nodules. The aim of the test is to help physicians identify patients whose nodules are likely to be benign, eliminating the risks they face from biopsies and surgeries.&nbsp;<a rel=\"nofollow\" href=\"http:\/\/www.indidx.com\/\" target=\"_blank\">www.IndiDx.com<\/a><\/p>\r\n<p>The company, co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners and The Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at&nbsp;<a rel=\"nofollow\" href=\"http:\/\/www.indidx.com\/\" target=\"_blank\">www.indidx.com<\/a><\/p>\r\n<p><strong>Source \/ For further information, please contact:<\/strong>&nbsp;<br \/>Patrick Tremblay&nbsp;<br \/><a rel=\"nofollow\" href=\"mailto:ptremblay@caprion.com\" target=\"_blank\">ptremblay@caprion.com<\/a>&nbsp;<br \/>Tel: (514) 513-1998<\/p>"];
			$("#dvExtra").html(content_array[0]);})();